Pharma Stocks
-
Traws Pharma Stock Jumps As Biotech Targets Hantavirus After Cruise Ship Deaths
NEWTOWN, Pa., May 8, 2026, 13:12 (ET) Traws Pharma Inc. on Friday announced plans to push ahead with possible clinical…
Read More » -
Jazz Pharmaceuticals plc Just Beat Earnings Expectations: Here’s What Analysts Think Will Happen Next
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) investors will be delighted, with the company turning in some strong numbers with its latest results.…
Read More » -
Are Estimate Revisions Reshaping ANI Pharmaceuticals’ (ANIP) Earnings Narrative After Its Q1 2026 Call?
ANI Pharmaceuticals, Inc. reported its Q1 2026 results and hosted its earnings call on May 8, 2026, after pre-announcing the…
Read More » -
Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q1 Loss, Beats Revenue Estimates
Crinetics Pharmaceuticals, Inc. (CRNX) came out with a quarterly loss of $1.23 per share versus the Zacks Consensus Estimate of…
Read More » -
Jazz Pharmaceuticals Stock Surged 105% Over the Past Year. Here’s What’s Driving the Move
Key Takeaways: Jazz Pharmaceuticals (JAZZ) is a biopharmaceutical company focused on developing and commercializing products for unmet medical needs, with…
Read More » -
Is TAK-881’s Reduced-Volume PID Infusion Data Altering The Investment Case For Takeda (TSE:4502)?
Earlier this month, Takeda Pharmaceutical reported that its pivotal Phase 2/3 trial of investigational PID therapy TAK-881 met its primary…
Read More » -
Zealand Pharma – Execution framework for share buy-back program
Zealand Pharma Company announcement No. 15 / 2026 Zealand Pharma – Execution framework for share buy-back program Copenhagen, Denmark, May…
Read More » -
A Look At Phathom Pharmaceuticals (PHAT) Valuation After Narrower Losses And Reaffirmed Profitability Timeline
Phathom Pharmaceuticals (PHAT) recently reported first quarter results showing a net loss of US$30.37 million, alongside reaffirmed 2026 guidance that…
Read More » -
Jazz Pharmaceuticals (JAZZ) Stock Trades Up, Here Is Why
What Happened? Shares of biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) jumped 5.4% in the afternoon session after the company reported strong…
Read More » -
Vertex Pharmaceuticals Stock: Q1 2026 Revenue Hits $2.99B With Full-Year Guidance Intact
Key Stats Current Price: $424 (May 5, 2026) Q1 2026 Revenue: $2.99B, up 8% YoY Q1 2026 Non-GAAP EPS: $4.47, up 10% YoY…
Read More »